HSIC stock: buy or sell?
November 15th, 2019
Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, animal health clinics, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide.
Should I buy HSIC stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Trading strategies are meant for helping you in the decision process of what stocks to choose and when is the best moment to buy them. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
None of our preferred buy setups matches with Henry Schein stock situation right now, therefore this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Henry Schein stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we collected 8 ratings published for HSIC stock in the last month.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-8-7||William Blair||Outperform||Market Perform|
|2019-3-25||Robert W. Baird||n/a||Neutral|
|2019-2-21||Royal Bank of Canada||Average||Sector Perform|
|2019-2-21||Barclays||Equal Weight||Equal Weight|
|2019-2-12||Royal Bank of Canada||Positive||Sector Perform|
HSIC stock analysis
Henry Schein shares stepped up 0.41% to $68.46 on Nov 15th.
Shares of Henry Schein stepped up a tiny 0.41% and closed at $68.46. Since Nov/4 when HSIC stock price broke up the SMA200d line, it gained $5.16 (8.15%). From a daily perspective, HSIC is in a short term uptrend after plotting its last bottom ($61.73, on Oct 25th) higher than the previous bottom, and its last top ($70.34, on November 7th) also over the previous top. Now trading in between its last bottom and last top HSIC might consolidate in a plain range, waiting to break out over $70.34 or down under $61.73. Since last July when SMA100d and SMA200d crossed up, HSIC price slipped $-0.44 per share (-0.64%).
After boosting a super good 8.14% in a week last week, Henry Schein closed this week at $68.46 and decreased an ugly -0.65%.
In a weekly time frame, Henry Schein stock is drawing an uptrend with rising tops and bottoms. Now trading in between its last bottom and last top, HSIC might consolidate in a flat-base, waiting to break out over or down under . Since price and SMA40w lines crossed up last week, HSIC climbed $5.16 (8.15%). Since late June when SMA20w and SMA40w crossed up, HSIC price slipped $-1.42 per share (-2.03%).
HSIC stock price history
HSIC IPO was on November 3rd, 1995 at $4.26 per share1. Since then, HSIC stock surged a 1,507.00%, with a yearly average of 62.80%. If you had invested right after HSIC's IPO a $1,000 in HSIC stock in 1995, it would worth $15,070.00 today.
1: Adjusted price after possible price splits or reverse-splits.
HSIC stock historical price chart
HSIC stock reached 52-week highs on June at $72.81, and all-time highs 2017-06-09 with a price of 73.33.
HSIC stock price target is $68.80How much a stock will be priced tomorrow or next week is quite unpredictable However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last 30 days we found 6 price predictions for Henry Schein stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-2-21||Royal Bank of Canada||Lowers Target||n/a||$62.00||-|
|2019-2-12||Royal Bank of Canada||Lowers Target||n/a||$69.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareAfter presenting its last earnings report on February, Henry Schein . As soon as we get its actual EPS from the earnings report, we will extend this review.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Henry Schein annual revenues rose a fine 5.94% to $13,202.00 M USD from $12,461.50 marked in 2017. Instead, its profit margin (compared to sales) stayed stable to 4.06%, that is $535.88 million.
|2013||$9,560 M||-||$444 M4.6%||-|
|2014||$10,371 M||8.49%||$466 M4.5%||4.95%|
|2015||$10,630 M||2.49%||$479 M4.5%||2.79%|
|2016||$11,572 M||8.86%||$507 M4.4%||5.79%|
|2017||$12,462 M||7.69%||$406 M3.3%||-19.83%|
|2018||$13,202 M||5.94%||$536 M4.1%||31.89%|
Quarterly financial resultsHenry Schein posted $3,375.20 M in sales for 2018-Q4, a 2.91% up compared to previous quarter. Reported quarter income marked $132.97 M with a profit margin of 3.94%. Profit margin remained stable a 0.24% compared to previous quarter when profit margin was 3.70%. When comparing turnover to same quarter last year, Henry Schein sales marked a slightly fine growth and raised a 1.72%.
|2017-Q1||$2,920 M||-||$141 M4.8%||-|
|2017-Q2||$3,060 M||4.79%||$136 M4.4%||-3.33%|
|2017-Q3||$3,161 M||3.30%||$138 M4.4%||1.45%|
|2017-Q4||$3,318 M||4.97%||$-9 M-0.3%||-106.18%|
|2018-Q1||$3,220 M||-2.94%||$140 M4.4%||-1,742.86%|
|2018-Q2||$3,327 M||3.30%||$141 M4.2%||0.71%|
|2018-Q3||$3,280 M||-1.41%||$121 M3.7%||-13.97%|
|2018-Q4||$3,375 M||2.91%||$133 M3.9%||9.46%|
Henry Schein ownershipWhen you are planning to invest in a company, it's worth to review its ownership structure.
Henry Schein shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 1.16% of all shares.
Bearish positions for HSIC stock account 0.00%, no big difference from last month.
For a better context understanding, the following table shows ownership data compared to other related companies:
|Market cap||$10.0 B||$18.2 B||$16.4 B||$22.3 B||$26.7 B|
|Total shares||146.7 M||208.3 M||292.4 M||85.8 M||180.2 M|
|Float shares||136.9 M||150.7 M||292.1 M||84.5 M||179.6 M|
|- Institutional holdings (%)||105.9%||68.0%||92.4%||90.9%||89.0%|
|- Insider holdings (%)||1.2%||27.1%||0.3%||1.6%||0.3%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, November 15th, 2019|
|Day range||$67.86 - $68.71|
|Average true range||$1.57|
|50d mov avg||$63.85|
|100d mov avg||$64.55|
|200d mov avg||$64.13|
Henry Schein performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. We compared Henry Schein against , Cardinal Health, IDEXX Laboratories, McKesson, Allscripts Healthcare Solutions, Owens & Minor and Patterson Companies in the following table:
|OMIOwens & Minor||36.83%||85.24%||-21.58%|
Henry Schein competitorsOne check before investing in any stock is to review a list of its competitors, in this case for Henry Schein. We picked 7 companies as Henry Schein competitors as they are in the same industry or have similar market objectives.
- Cardinal Health (CAH)
- IDEXX Laboratories (IDXX)
- McKesson (MCK)
- Allscripts Healthcare Solutions (MDRX)
- Owens & Minor (OMI)
- Patterson Companies (PDCO)
Latest HSIC stock news
- Seeking AlphaPreparing For The End Of The Cycle (Part XIV): Henry ScheinMarch 14, 2019
- InvestorPlace3 Big Stock Charts for Wednesday: Henry Schein, Alaska Air Group and PulteGroupMarch 6, 2019
- Seeking AlphaWhy We Believe Henry Schein's Upcoming Animal Health Spin-Off Will Unlock 30% To 50% UpsideSeptember 26, 2018